Abstract
Compound (4-bromophenyl)-1,3,4-thiadiazol-N,N'-diphenylphosphonic diamide 3j exhibited the promising antiproliferative activity against MCF-7 breast cancer cells, with an IC50 of 26 µM. Combination studies revealed that compound 3j acts synergistically with several clinically relevant anticancer agents, including an AKT inhibitor, everolimus, docetaxel, doxorubicin, and 4-hydroxytamoxifen, as evidenced by high synergy scores in MCF-7 cells.
Keywords
antiproliferative agents
cancer
Heterocycles
organophosphorus compounds
thiadiazole
Funders
Russian Science Foundation
22-13-00161-P